Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics

Transdermal delivery of drug through the skin provides a successful method for the treatment of rheumatoid arthritis (RA). However, stratum corneum (SC) presents the main barrier for transdermal delivery. In order to overcome this barrier many strategies have been adopted. Nanocarriers used to improve dermal and transdermal delivery are colloids including liposomes, ethosomes, transferosomes and bilosomes.Lornoxicam (LX) is an oxicam derivative. It{u2019}s an anti-inflammatory, antipyretic and analgesic drug prescribed for indications like rheumatoid arthritis. It acts by inhibiting phospholipase A2 resulting in the inhibition of arachidonic acid synthesis and controlling prostaglandins and leukotriene synthesis eventually, leading to anti-inflammatory, immunosuppressive and the anti-proliferative effect. It is practically insoluble in water; it needs frequent oral administration due to its short half- life (3-4 h). Moreover, parenteral administration isn{u2019}t recommended against chronic condition. Accordingly, our study aims to develop LX as controlled release nanocarriers transdermal gels in order to improve drug delivery across the skin and to evaluate in vivo analgesic and anti-inflammatory activity with decreased GIT, renal and hematological adverse effects

Issued also as CD